The concept of hematopoietic stem cell (HSC) niche was formulated in 1978, but HSC niches remained unidentified for the following two decades largely owing to technical limitations. Sophisticated live microscopy techniques and genetic manipulations have identified the endosteal region of the bone marrow (BM) as a preferential site of residence for the most potent HSC -able to reconstitute in serial transplantswith osteoblasts and their progenitors as critical cellular elements of these endosteal niches. This article reviews the path to the discovery of these endosteal niches (often called 'osteoblastic' niches) for HSC, what cell types contribute to these niches with their known physical and biochemical features. In the past decade, a first wave of research uncovered many mechanisms responsible for HSC homing to, and mobilization from, the whole BM tissue. However, the recent discovery of endosteal HSC niches has initiated a second wave of research focusing on the mechanisms by which most primitive HSC lodge into and migrate out of their endosteal niches. The second part of this article reviews the current knowledge of the mechanisms of HSC lodgment into, retention in and mobilization from osteoblastic niches.
Introduction
Following the discovery that virtually all long-term reconstituting hematopoietic activity is contained within the bone marrow (BM) tissue in adult mammals, 1,2 many aspects of hematopoietic stem cell (HSC) regulation within the BM have now been elucidated. Some of the most significant discoveries have been that (1) HSC must reside in specialized niches in the BM to exert their function properly, 3 and (2) a small proportion of HSC and more committed hematopoietic progenitors cells (HPC) physiologically traffic continually from the BM into the circulation 4 and concomitantly re-home to the BM. 5 Although little is known about the mechanisms leading to the spontaneous release of a small proportion of hematopoietic stem and progenitor cells (HSPC) from their niches into the blood, 6 ,7 much more research has been devoted to HSPC homing into the BM and extraphysiological mobilization as observed following the administration of therapeutic doses of cytokines, such as granulocyte colony-stimulating factor (G-CSF), cytotoxic drugs or chemokine analogs. [8] [9] [10] The first HSC hitch-hiker's guide to getting in and out of the BM It is now well established that homing to the BM tissue involves a capture step in which circulating HSPC directly interact with the BM endothelium via cell-cell adhesive interactions. This is made possible by the unique feature of BM sinusoidal endothelial cells, to constitutively express the adhesion molecules (1) P-selectin (CD62P), (2) E-selectin (CD62E) and (3) vascular cell adhesion molecule-1 (VCAM-1 or CD106).
11,12 HSPC express receptors for both endothelial selectins, most importantly P-selectin glycoprotein ligand-1 (or CD162), CD44, 13 and other less well-defined E-selectin receptors, 14 as well as receptors for VCAM-1, such as integrins a4b1, 15,16 a4b7 17 and a9b1. 18, 19 Experiments in mice using function-blocking antibodies or targeted deletions of these genes have clearly shown their essential role in HSPC homing to the BM. P-and E-selectin mediate the initial rolling of fast flowing HSPC onto BM endothelium. Once slowed, HSPC can firmly adhere to the vasculature via integrins and transmigrate through the endothelium into the BM stroma 15, 20, 21 to migrate and lodge into their respective niches. Although these same three cell adhesion molecules are utilized to recruit immune cells to sites of inflammation/injury in other tissues, they only become expressed at the surface of endothelial cells after pro-inflammatory stimuli. A unique feature of BM endothelium is the constitutive expression of endothelial selectins and VCAM-1 cell adhesion molecules enabling homing of HSPC into the BM in steady-state conditions. The chemokine CXCL12 (or stromal cell-derived factor SDF-1) also plays a critical role in recruiting HSPC into the BM and guiding them to their niches by interacting with its receptor CXCR4 expressed by HSPC. This CXCL12:CXCR4 interaction triggers chemotaxis via intracellular GTPase proteins. Indeed, pre-treatment of human HSPC with a blocking anti-CXCR4 antibody impairs their homing into the BM of non-obese diabetes/severe-combined immunodeficiency (NOD/SCID) mice. 22 Similarly in the mouse, homing of HSPC isolated from the fetal liver of CXCR4 À/À mice (CXCR4 gene deletion is perinatally lethal) have a severe homing defect in host BM. However, this homing defect can be rescued by increasing the cell dose, 23 possibly because other cytokines such as KIT ligand (KL) can also promote HSPC adhesion and migration via integrin activation. 16, 24 Integration of the adhesive and chemotactic signaling from CXCR4, c-KIT and many other receptors that contribute to homing (such as adrenergic and prostaglandin E2 receptors) depends on several small GTPases such as Rac1, Rac2, 25 cdc42, 26 and guanine nucleotide binding protein complexes Gi 27 and Gs, 28 which could be upstream of Rac and cdc42. Indeed, pharmacological inhibition or conditional deletion of genes encoding these proteins impairs HSPC homing. In addition to recruiting HSC to the BM, CXCL12 is also critical to the retention of HSPC within the BM and consequently in mobilization. This will be reviewed further below.
HSC mobilization is not the mirror image of homing
During the past decade, it has also emerged that HSPC mobilization is not the reverse of homing, but rather a disruption of the mechanisms that retain HSPC within the BM and their niches as the mechanisms of homing do not perfectly overlap or mirror those of retention and mobilization. For instance, conditional deletion of both Rac1 and Rac2 genes in HSPC causes a mild homing defect (40% reduction in homing of colony-forming cells 16 h post transplant), whereas it causes massive HSPC mobilization in vivo. 25 Similarly, homing of CXCR4 À/À HSPC is severely impaired but can be rescued by the administration of large cell doses. However, once engrafted long term into recipients, CXCR4
À/À HSPC are poorly retained in the BM and large numbers circulate in the blood. 23 From these experiments, it was concluded that mobilization is not caused by a homing defect, but rather by a breakdown of retention mechanisms. The mechanistic difference between homing and retention in the BM is further illustrated by the conditional deletion of the Gs a gene. Although inhibition of the heterotrimeric guanyl binding protein Gi, which inhibits adenyl cyclase and the formation of cAMP, impairs both homing to and retention within the BM, 27, 29 conditional deletion of Gs a in hematopoietic cells, which is necessary to activate adenyl cyclase and the formation of cAMP, prevents HSPC homing to the BM during fetal development, as well as in adults following transplantation without affecting HSPC retention within the BM. 28 This suggests that cAMP, whose synthesis is controlled by the dual action of Gs and Gi proteins, may be rheostat regulating homing and retention differentially. 30 
Are proteases important?
Conditional deletion experiments have delineated some of the most critical pathways in HSPC retention and mobilization. In particular, the VCAM-1/a4 integrin interaction, the CXCL12/ CXCR4 interactions and the signaling mediated by Gi protein, Rac1 and 2, and cdc42. Conditional deletion of any of these genes 23, 25, 26, [31] [32] [33] or treatment with pertussis toxin that blocks Gi protein 29 causes massive HSPC mobilization into the blood. Nonetheless, how these mechanisms are disrupted during clinical mobilization, for instance, following the administration of G-CSF or cytotoxic therapy, is still not completely elucidated and under intense investigation. We and others have found that in humans and inbred mouse strains that mobilize well in response to G-CSF or chemotherapy (such as BALB/c or 129Sv), neutrophil proteases such as neutrophil elastase, cathepsin G, matrix metalloproteinase-9 or membrane type-1 matrix metalloproteinase accumulate in the BM space with concomitant downregulation of their naturally occurring inhibitors serpins and tissue inhibitors of metalloproteinases. [34] [35] [36] [37] [38] [39] [40] As these proteases cleave and inactivate a range of proteins involved in HSPC retention within the BM, such as VCAM-1, 34, 35 CXCL12, its receptor CXCR4, 41, 42 KIT 43 and KL, 44 they are tempting candidates to mediate some aspects of mobilization. However, the whole concept that secreted neutrophil proteases contribute to HSPC mobilization has been questioned by the fact that targeted deletion of these genes in the C57BL/6 inbred mouse strain does not decrease mobilization in response to G-CSF. 45 This was highly unexpected as in humans, shed soluble VCAM-1 fragments resulting from proteolytic cleavage have increased concentrations in the blood of mobilized donors, and this increase is correlated with the mobilization response. 34, 46 In addition, soluble VCAM-1, neutrophil proteases and circulating HSPC also increase in idiopathic myelofibrosis. 47 Interestingly, inbred mouse strains that mobilize poorly in response to G-CSF (typically C57BL/6, the strain in which most protease knockout have been made) have much lower release of neutrophil proteases in the BM in response to G-CSF than strains that mobilize well (such as BALB/c and 129Sv, strains in which initial in vivo studies on proteases and protein cleavages were carried out). Therefore, before totally excluding the possible role of proteases in HSPC mobilization, experiments should be repeated in knockout mice backcrossed onto BALB/c, DBA/2 or 129Sv strains, which are known to mobilize well and release large amounts of proteases in the BM in response to G-CSF. Furthermore, although protease knockout C57BL/6 mice still mobilize in response to G-CSF, mobilization can be dramatically reduced by transient inhibition of these same proteases following injection of protease inhibitors. 36, 39, 42 In summary, although proteases are likely to be an important mechanism of HSC mobilization in normal circumstance, other mechanisms are available. Taken together, experiments in C57BL/6 mice show that there are alternative mechanisms that can lead to HSPC mobilization in response to cytokines and chemotherapy. Indeed, the C57BL/6 strain has been very helpful in identifying such alternative mechanisms of HSPC mobilization involving, for instance, the transmembrane dipeptidyl peptidase CD26, 48, 49 complement cascade activation and complement fragments C3 and C5, 50, 51 or the plasminolytic pathway. 52, 53 Although these studies have provided invaluable insights on how HSPC home into and mobilize from the whole BM tissue, they did not investigate the mechanisms of migration and lodgment into their specific niches, and whether mobilization involves perturbation within the niche itself. The recent identification of cellular and molecular components of HSC niches in the BM has initiated a second wave of research to dissect the mechanisms of homing into and mobilization from these niches.
Evidence supporting osteoblastic (or endosteal) niches
The nature and composition of HSC niches remained unknown until the second half of this decade. Preceding the formulation of the HSC niche concept by Schofield, Brian Lord and co-workers provided the first evidence that the distribution of primitive HSPC was not isotropic throughout the mouse BM, but enriched in proximity to the bone -the endosteal region. By applying serial BM flushes with increasing strength, BM leukocyte fractions were eluted radially according to their distance from the central longitudinal axis of the BM. Short-term reconstituting spleen colony-forming units were three times more frequent in the endosteal region within 50 mm of the bone surface than in the more central BM. 54 This anisotropic distribution of most primitive HSPC led Russell Taichman to hypothesize that boneforming osteoblasts may be the critical cells that support HSC in vivo, and showed that in culture, human osteoblasts purified from trabecular bones could support the expansion of long-term culture-initiating cells (LT-CIC) derived from CD34 þ human BM cells 55 ; an effect mediated in part by the secretion of G-CSF and
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In and out of hematopoietic stem cell nicheshepatocyte growth factor by osteoblasts. 56 Altogether, these studies showed that most primitive HSPC preferentially reside near and migrate close to the endosteum, and that osteoblast lineage cells could support these HSPC in vitro. This suggested that the endosteal region and osteoblast lineage cells provide a specific microenvironment favorable to HSC in vivo.
In 2003, two papers published in the same issue of Nature propelled osteoblasts into the spotlight. Two strains of genetically modified mice with increased osteoblast function and bone formation constructed in David Scadden's and Liheng Li's laboratories had increased the number of HSC and hematopoiesis in the BM. In the first paper, mice overexpressed a constitutively active mutant of parathyroid hormone 1 receptor (PTHR1), the common receptor for parathyroid hormone (PTH) and paracrine PTH-related peptide specifically under the control of the 2.3-kb fragment of the rat collagen 1a promoter, which is specific of maturing and mature osteoblasts (col2.3PTHR1 mice). 58 As expected, constitutive activation of PTHR1 in osteoblasts dramatically increased trabecular bone formation in tibial metaphysis at the expense of the BM space. Less expected was the doubling in the frequency of Lin À Sca1 þ KIT þ HSPC, LT-CIC and long-term competitive repopulating cells (LT-CRC), whereas the frequency of more mature colonyforming cells was unaltered. In these mice, expression of interleukin-6, KL and CXCL12 by osteoblasts was increased and a direct role of the transgenic BM stroma in supporting wild-type (WT) LT-CIC was shown in vitro. The role of PTH and paracrine PTH-related peptide in supporting HSC niche function was further supported by the observation that daily administration of PTH to WT mice also increased Lin À Sca1 þ KIT þ HSPC, LT-CIC and LT-CRC frequencies in the BM, and increased the engraftment of suboptimal doses of BM donor cells into lethally irradiated recipients treated with PTH. 58 In the second paper, the bone morphogenic protein receptor BMPR1a gene, which is expressed by osteoblasts and most hematopoietic lineages, except Lin À Sca1 þ KIT þ HSPC, was floxed and deleted in adults mice following induction of the Mx1Cre transgene with polyI:polyC. The somatic deletion of the BMPR1a gene resulted in a phenotype similar to that observed in col2.3PTHR1 transgenic mice, including increased bone formation and reduced BM cavity associated with increased absolute number of Lin À Sca1 þ KIT þ HSPC, LT-CIC and LT-CRC per femur, as well as lower HSPC proliferation in vivo as measured by bromodeoxyuridine incorporation. 59 The suggestion that osteoblasts and endosteum support HSC in vivo was further supported by refined in vivo and ex vivo three-dimensional imaging of HSC in whole mouse bones. In the calvaria, a flat bone which unlike long bones is not formed by endochondral ossification but by intramembranous ossification,
À phenotypic HSC rapidly homed within 20 mm of the endosteum and 10 mm (or two-cell diameters) from osteoblasts in irradiated recipients, whereas these HSC homed more distant from the endosteum and osteoblasts in non-irradiated recipients. On the other hand, more mature HPC such as
þ progenitors and linage committed Lin À Sca1 À KIT þ HPC homed more distant from osteoblasts and endosteum. 60 Similar three-dimensional microscopy studies on whole femurs explanted 4 h post transplant showed a preferential homing of 60% transplanted Lin À Sca1 þ KIT þ HSPC within two-cell diameters from osteoblasts at the trabecular endosteum in irradiated recipients but not in non-irradiated recipients. Interestingly, transplanted HSPC proliferated extensively in irradiated recipients in the trabecular metaphysis but not in the diaphysis 1 week post transplant. In non-irradiated recipients, transplanted HSPC did not proliferate and were lost from recipient BM within 2 weeks. 61 These two congruent studies and others 62, 63 confirmed that transplanted HSC rapidly homed to specific niches located within two-cell diameters from osteoblasts at endosteal surfaces in both flat and long bones and that these niches need first to be vacated (for example, following lethal irradiation) in order for HSC to successfully home in these endosteal niches. Furthermore, a recent study has shown in adult mice that LT-CRC with the capacity to serially transplant are deeply quiescent in steady state, dividing on average once every 145 days, or five times in a mouse lifetime. 64 These deeply quiescent, slow-cycling HSC (able to retain bromodeoxyuridine over a 70-day chase) also reside close to the endosteal surfaces 64 and distal to rapid blood flow.
The notion that the bone provides a privileged environment supporting HSC self-renewal is also supported by experiments in which bone ossicles are grown ectopically under the mouse skin or kidney capsule. In these experiments, ossicles are formed by transplanting cultured plastic adherent mesenchymal stromal cells in a gelatin sponge under the skin. 66 At 21 days post transplant, bone ossicles develop containing BM with HSC, leukocytes and endothelium derived from the host. This ossicle BM is very similar in composition to endogenous femoral BM and contains HSC defined as LT-CRC. Interestingly, administration of bone anabolic PTH during the growth of the ossicles doubles bone density and trebles LT-CRC frequency in the ossicles. 67 When BM cells are injected directly into ectopic ossicles or in the circulation after lethal irradiation to eliminate host HSC, donor HSC colonize and self-renew within the ossicles, and reconstitute hematopoiesis. 67 Taken together, these data show that small ectopic ossicles can form bona fide HSC niches supporting HSC self-renewal and hematopoietic reconstitution.
The proto-oncogene c-myc has been proposed to play a critical role in the regulation of HSC self-renewal in the endosteal niche. 68 This conclusion was based on the findings that:
À HSC express much lower levels of c-myc than their more differentiated and committed progenies; (2) conditional deletion of c-myc in hematopoietic cells enhances HSC self-renewal with the accumulation of HSC in the BM tissue, but inhibits their differentiation; (3) once transplanted c-myc-deficient HSC home and lodge into endosteal niches, self-renew and accumulate in host BM, but fail to differentiate into mature leukocytes; and (4) overexpression of c-myc compromises HSC reconstitution potential of lethally irradiated hosts. 68 Although c-myc is an important rheostat that regulates HSC self-renewal versus differentiation, localization analyses of HSC in the BM and endosteum are necessary to confirm whether c-myc also regulates HSC location. For instance, do self-renewing c-mycdeficient HSC accumulate specifically in endosteal niches, and
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Are mature osteoblasts important? Here comes the osteoprogenitors
Most studies show that following transplantation, a proportion of phenotypic HSC rapidly homed to endosteal niches within two-cell diameters (or 10 mm) of osteoblasts lining the endosteum. 33, 59, 61, 69 However, in non-manipulated naïve mice, an important proportion of these phenotypic HSC also reside in perivascular locations in direct contact with the abluminal side of endothelial cells away from the endosteum. 33, 70, 71 From these data emerged the concept of vascular niches. Importantly, these two niches cannot be easily distinguished in flat bones such as the calvaria, in which the BM is so thin that most osteoblasts are perivascular, 60 or in femurs where 30% of osteoblasts in trabecular areas are in the vicinity of the vasculature. 61 Therefore, the vascular and endosteal niche need not be mutually exclusive and are likely to partially overlap in location and function. 71 In addition, the initially described direct association of spindle-shaped N-cadherin þ osteoblasts with N-cadherin þ HSC 59 has been challenged by a competing group that could not detect N-cadherin in functional HSC. 72, 73 Further doubts on the role of mature osteoblasts in directly supporting HSC was provided by col2.3HTK transgenic mice, in which the suicide Herpes virus thymidine kinase (HTK) gene is specifically expressed in maturing osteoblasts under the control of col2.3 promoter. When these mice are treated with ganciclovir, this guanosine analog is phosphorylated and incorporated into DNA specifically killing osteoblasts expressing HTK. Osteoblast depletion in vivo resulted in ablation of the BM and relocation of hematopoiesis and HSC in the spleen and the liver. 74 However, the surprise was that HSC ablation in the BM was slow, 2-3 weeks after osteoblast depletion, whereas medullar B lymphopoiesis, which requires functional osteoblasts in vivo and in vitro, was ablated within few days. 75 Similarly, in a mouse model of chronic inflammatory arthritis, bone formation was reduced with reduced number of B-cell progenitors in the BM. However, the content in phenotypic and functional LT-CRC was unaltered. 76 This disconnection between mature osteoblasts and B lymphopoiesis on the one hand, and slow mobilization of medullar HSC on the other, questioned the role of mature osteoblasts in supporting HSC niches. 77 Furthermore, deletion of the biglycan gene, an extracellular protein produced by mature osteoblasts and chondrocytes, results in reduced trabecular bone and osteoblasts, but not in reduced frequency of phenotypic HSC and LT-CRC in the BM. 72 In fact, it has very recently emerged that osteoprogenitors are more important than mature osteoblasts in supporting HSC. 78 Global gene regulation was targeted specifically in either mature osteoblasts or osteoprogenitors in two distinct mouse strains by breeding mice with a floxed Dicer-1 gene (necessary to the processing and maturation of all regulatory microRNA), with mice containing a Cre recombinase driven by either the osterix promoter -active specifically in osteoprogenitors (osxCre þ Dicer1 f/f ), or by the osteocalcin promoter -only active in mature osteoblasts (osxCre þ Dicer1 f/f ). Both strains had similar bone defects; however, only osxCre þ Dicer1 f/f mice had a severe hematopoietic defect, whereas in sharp contrast, oscalCre þ Dicer1 f/f had normal hematopoiesis. 78 The specific ablation of microRNA in osteoprogenitors resulted in a myelodysplastic syndrome with peripheral pancytopenia. Furthermore, in the BM, phenotypic HSC were closer to the endosteal surface than normal and proliferated more; B lymphopoiesis was reduced and myelopoiesis increased. Transplantation of WT HSC into lethally irradiated osxCre þ Dicer1 f/f recapitulated the phenotype. Finally, secondary leukemia emerged in these mice showing that a defective HSC niche can also support the expansion of malignant clones that would be repressed in a normal niche. Interestingly, deletion of the Shwachman-Diamond-Bodian syndrome (Sbds) gene from osteoprogenitors, whose expression is reduced in osxCre þ Dicer1 f/f osteoprogenitors, resulted in a similar phenotype. 78 Todate, these results provide the most compelling evidence that osteoprogenitors are crucial to HSC function and essential components of HSC niches.
What do HSC particularly like in endosteal niches?
Although the precise cellular and molecular composition of endosteal HSC niches is far from fully understood, it clearly involves cells from the osteoblastic lineage, particularly osteoprogenitors. In addition to this, CXCL12-abundant reticular (CaR) cells have been identified in mouse BM in direct contact with phenotypic HSC regardless of the location of the niche (endosteal or vascular). 33 Further characterization of these cells will enable to better understand how niches control HSC fate. þ are spatially associated with these nestin þ cells in the BM, and upon transplantation, HSC rapidly lodge near these nestin þ cells. Selective depletion of nestin þ cells in the BM resulted in a 50% reduction in phenotypic HSC numbers in the BM, and a 90% reduction in homing of transplanted colony-forming cells. These nestin þ MSC express high levels of KL, CXCL12 and angiopoietin-1 (ang-1), cytokines well known to promote HSC selfrenewal. 80, 81 Therefore, several cell types from the mesenchymal and osteogenic lineages may act in concert to form HSC niches.
A number of proteins with effects on HSC proliferation and self-renewal in vivo or in vitro have been found to be expressed by osteoblasts and osteoblast lineage cells (Table 1). CXCL12   33 and VCAM-1, 32 which are critical to the retention of HSPC within the whole BM tissue, are also expressed by osteoblast lineages cells and osteoblasts at the endosteum. 75, [82] [83] [84] In addition, many proteins that affect HSC proliferation and selfrenewal capacity are also expressed by osteoblasts such as ang-1, KL, thrombopoietin, BMP-4, secreted frizzled related protein-1 (sfrp-1) and connexin-43 (Table 1) . Mutations, deletions or overexpression of these genes, which are expressed by osteoblast lineage cells, all alter HSC function in vivo (Table 1) . Osteoblasts also express a number of Notch ligands such as Jagged-1 and -2, Delta-1 and -4, and Hes-1 and -5. 85 Furthermore, experiments using reporter mice in which cells become fluorescent when Notch signaling is activated have shown that Notch signaling is activated in phenotypic HSC in col2.3PTHR1 transgenic mice. 58 Inhibition of Notch signaling by retroviral expression of a dominant-negative mutant of xenopus suppressor of hairless, a pan inhibitor of Notch signaling, also resulted in compromised reconstitution and increased HSC differentiation in vivo. 86 The fact that osteoblasts express several Notch ligands, which may trigger several Notch receptors on HSC, may explain why deletion of Jagged-1 and Notch-1 does not compromise hematopoiesis in vivo.
87 Notch and Wnt signaling pathways are coactivated in vivo, 86 suggesting an important role for the latter, a conclusion strengthened by the finding that HSC function is altered in the BM of mice after deletion of sfrp-1 gene in the stroma (sfrp1 is a canonical Wnt signaling inhibitor), or overexpression of the Dickkopf-1 transgene (another Wnt signaling inhibitor) in osteoblast lineage cells under the control of the col2.3 promoter 88, 89 (Table 1 ). In addition to proteins, endosteal niches have a peculiar physical-chemical environment compared with the central BM. The endosteum, particularly in the metaphyseal spongiosa where most HSC reside, is the site of active bone remodeling with coupled bone formation and degradation. Consequently, soluble Ca 2 þ ions are released by osteoclasts degrading the bone and re-deposited in the neo-formed bone matrix or osteoid. Ca 2 þ concentrations around active osteoclast-degrading bone fragments can reach up to 40 mM, 90 thus creating a Ca 2 þ gradient from the endosteal surfaces. HSC are equipped with Ca 2 þ receptors sensing this gradient and enabling them to home to endosteal niches. The second characteristic of HSC niches are their very low blood perfusion and oxygen tension. In steady state, the endosteal region of the BM is hypoxic with less than 2% O 2 , with high cellular content in the hypoxiainducible factor-1a, 91 an O 2 -labile transcription factor rapidly degraded by the proteasome when O 2 concentration is in excess of 2%. 92 Furthermore, long-term reconstituting HSC bind to chemical probes such as pimonidazole that detect hypoxic environment in vivo, 93 suggesting that most potent and primitive HSC reside in a hypoxic environment in the BM. We have recently found that the most potent and deeply quiescent HSC (retaining bromodeoxyuridine label for over 70 days with unique ability to serially transplant in secondary recipients) are located in niches with the poorest blood perfusion. Indeed, following intravenous injection of Hoechst33342, a cell-permeable fluorescent dye was administered for the last 10 min before being killed; only phenotypic HSC not exposed to this dye in the BM in vivo (furthest from rapid blood flow) were able to serially transplant, whereas HSC of identical phenotype, which had incorporated some dye in vivo (located in more perfused niches), were less potent with faster cycling and able to reconstitute a single host only. 65 The poor perfusion of niches, which contain the most potent HSC, may be due to very low blood velocity in BM endothelial sinusoids. Indeed, sinusoidal blood flow at the endosteum of the rabbit fibula is only onetenth of that in capillaries. 94 In addition, mathematic modeling predicts that a layer of two myeloid progenitors is sufficient to deplete most O 2 provided by a nearby BM sinusoid. N-cadherin N-cadherin knockdown or overexpression of dominant-negative mutant in HSC increases HSC proliferation, reduces lodgment to the endosteum and compromises long-term reconstitution 103, 104 Annexin II Anti-annexin II antibody treatment of HSC reduces HSPC homing to the BM, and long-term reconstitution following transplant. HSPC adhere less to annexin II-deficient osteoblasts 106 Pathways Notch signaling Inhibition compromises HSC self-renewal and increases differentiation 58, 86 Wnt signaling Overexpression of Dikkopf-1 in osteoblasts to inhibit Wnt signaling increases HSC proliferation and decreases serial reconstitution (HSC self-renewal) 89 Physicochemical properties Soluble calcium ion HSC lacking the calcium receptor have hypocellular BM with reduced number of HSC. They fail to lodge near endosteum upon transplantation 98 Low blood perfusion, hypoxia Dormant serially transplantable HSC reside in poorly perfused hypoxic niches and the endosteal niches are hypoxic 65, 91, 93 Abbreviations: BM, bone marrow; BMP-4, bone morphogenetic protein 4; HSC, hematopoietic stem cell; HSPC, hematopoietic stem and progenitor cells; Sfrp1, secreted frizzled related protein-1; TPO, thrombopoietin; VCAM-1, vascular cell adhesion molecule-1.
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It is therefore possible that the blood velocity in these sinusoids is so low that phenotypic HSC need not be located very far away from these sinusoids to be in hypoxia. Thus, exposure to blood perfusion may determine HSC function and niche characteristics more than absolute distance from the vasculature. Low blood velocity in BM sinusoids may therefore reconcile the observations that (1) most long-term reconstituting HSC reside in hypoxic 93 and poorly perfused areas of the BM, and (2) phenotypic HSC are also observed in proximity to blood sinusoids. 33, 70 Other consequences of poor perfusion of HSC niches containing the most dormant and primitive HSC may also be (i) greater concentration of locally secreted factors/mediators produced by support cells of the niche (factors/mediators diluted by the blood flow in more perfused/less dormant niches), and (ii) very low concentrations of blood-borne nutrients and O 2 . 65 
What drives HSC lodgment into endosteal niches?
Once circulating HSC have crossed the endothelium into the BM (homing phase), they rapidly migrate through the BM stroma to lodge in their niches near the endosteum (lodgment) within a few hours. 96, 97 Many molecular determinants of HSC lodgment into their endosteal niches have recently been identified. Most of these signals are either produced by osteoblasts and osteoblast lineage cells, deposited in the extracellular matrix at or near the endosteum, or released from the endosteum during its remodeling.
Calcium
Soluble Ca 2 þ ions released from the remodeling endosteum together with the calcium ion receptor CaR expressed by HSPC are essential to HSC lodgment at the endosteum. CaR-deficient mice have hypocellular BM, reduced frequency of phenotypic Lin À Sca1 þ KIT þ HSPC and LT-CIC in the BM, and consequently increased the number of Lin À Sca1 þ KIT þ HSPC in the blood and spleen. Furthermore, on histological sections, fluorescently labeled Lin À Sca1 þ KIT þ HSPC from CaR-deficient mice failed to properly lodge within two-cell diameters of the endosteum of WT recipients, 98 showing that soluble Ca 2 þ and CaR are critical to HSC lodgment into endosteal niches.
Osteopontin
Osteopontin, a bone matrix protein particularly abundant at the endosteum, is produced by both osteoblasts and osteoclasts and exerts many functions on HSC. Lodgment of transplanted WT Lin À Sca1 þ KIT þ HSPC at the endosteum is reduced in nonablated osteopontin-deficient recipients compared with WT recipients. 99 In one report, osteopontin negatively regulated HSC proliferation in vivo. Indeed, phenotypic HSC were more numerous and proliferative, as measured by bromodeoxyuridine incorporation, in the BM of osteopontin-deficient mice. 99 In another report, osteopontin deletion from the mouse BM stroma was found to decrease apoptosis of Lin À Sca1 þ KIT þ HSPC in the BM and increase expression of Jagged-1 and ang-1 by osteoblasts, suggesting that osteopontin is also a negative regulator of niche function. 100 These effects of osteopontin are not mediated by the intact protein, but via a cryptic site exposed upon proteolytic cleavage by thrombin. Once cleaved by thrombin, these osteopontin fragments were chemoattractive to HSPC via integrins a4b1 and a9b1 expressed at the surface of both mouse and human HSPC. 18 Consequently, mice with deleted osteopontin gene have a 2-to 3-fold increase in the number of circulating Lin À Sca1 þ KIT þ HSPC in steady state. 18 Integrin a4b1, which is critical to HSPC homing and retention within the BM tissue, is also critical to HSC lodgment into the endosteal region as integrin a4-deficient Lin À KIT þ cells failed to preferentially lodge at the endosteum of WT mice. 63 Considering that two of the integrin a4 ligands are expressed by osteoblast lineage cells, namely VCAM-1 and osteopontin, this is not so surprising.
Transmembrane KL
Similarly, transmembrane KL, which is also expressed by osteoblasts, is necessary for HSC lodgment near the endosteum. Transplanted WT HSPC have significantly reduced lodgment at the endosteum of Steel Dickie (Sl d /Sl d ) mice, which express only a soluble form of KL due to a deletion of the region encoding the transmembrane and intracellular domains. 101 
Cadherins
In the initial work describing enhanced HSC number in the BM cavity of mice with somatic deletion of the BMPR1a gene, 59 HSC directly attached to spindle-shaped osteoblasts. Both cell types were described to express the cell adhesion molecule N-cadherin. However, the expression of N-cadherin by HSC was later contested by Sean Morrison's group who could not detect N-cadherin by quantitative reverse transcriptase-polymerase chain reaction or flow cytometry in sorted
þ HSC or in HSC from transgenic mice expressing the lacZ reporter under the N-cadherin promoter. 72 Furthermore, polyI:polyC treatment of Mx1Cre þ N-cadherin fl/À mice, which deletes the N-cadherin gene from both osteoblasts and hematopoietic cells did not alter the frequency or the number of phenotypic HSC in the BM, longterm reconstitution potential in competitive repopulations assays, nor their serial reconstitution potential. 73 Following a mediation by Len Zon, it was concluded that HSC either do not express N-cadherin or the level is so low or expressed by a very limited HSC subpopulation that N-cadherin is not reliably detected. Furthermore, serial dilution analysis in competitive repopulations assays of HSC that underwent N-cadherin gene deletion using the Mx1Cre þ N-cadherin fl/À mice model showed that N-cadherin deletion in HSC did not alter long-term engraftment and reconstitution. 102 In a more recent twist, however, Toshio Suda's laboratory has recently reported that lentiviral transduction of a dominant-negative mutant of N-cadherin that inhibits both homotypic and heterotypic interactions of N-cadherin in donor HSC significantly reduced lodgment to the endosteum and compromised long-term engraftment and chimerism, whereas overexpression of WT N-cadherin caused increased lodgment at the endosteum and increased ability to self-renew and serially reconstitute lethally irradiated hosts. 103 Finally, overexpression of two distinct short hairpin RNA specific for N-cadherin in HSC, accelerated HSC proliferation, severely reduced long-term engraftment in a competitive repopulation assay and reduced HSC lodgment to endosteal surfaces, 104 a result at odd with the conditional deletion of the N-cadherin gene. 102 Therefore, the expression of N-cadherin on HSC and its role on HSC retention and lodgment are still controversial and need further clarification.
Annexin II
Annexin II, which forms a heterotetramer with the Ca 2 þ -binding protein S100A10 and is involved in plasminogen binding and
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In and out of hematopoietic stem cell niches J-P Lévesque et al activation, 105 is expressed on both BM endothelial cells and osteoblasts. 106 Annexin II may play an important role in the lodgment of HSC in osteoblastic niches as adhesion of WT HSPC to annexin II-deficient osteoblasts is reduced by 50%. Furthermore, treatment of transplant recipients with blocking antibodies or annexin II peptide reduced WT HSPC homing to the BM and compromised long-term reconstitution. 106 However, as annexin II is expressed by both endothelial cells and osteoblasts, it is not clear from these experiments whether annexin II is necessary for the initial adhesive interaction between BM endothelial cells and circulating HSPC or for the final lodgment in endosteal niches. Further experiments are clearly needed.
What drives HSC out of endosteal niches?
Cytokines such as G-CSF mobilize long-term reconstituting HSC. One would anticipate HSC in endothelial niches to be rapidly mobilized owing to their proximity to the circulation. However, as most serially reconstituting dormant HSC are found in poorly perfused hypoxic niches 65, 91, 93 and are enriched at the endosteum, 64 one would expect a proportion of HSC to be also mobilized from endosteal niches. Recent research has clearly shown that mobilizing cytokines and cytotoxic drugs do indeed severely alter the endosteal landscape.
Inhibition of osteoblasts and bone formation
As early as the mid-1990s, before the recognition of endosteal and osteoblastic HSC niches, bone pain was readily identified as a common side effect of G-CSF treatment in humans. 107, 108 In 1998, we found that short-term G-CSF regimens to mobilize HSPC transiently inhibited bone formation and osteoblast function in humans with decreased osteocalcin concentration in blood plasma. 109 The identification of endosteal niches renewed interest in the effect of mobilizing agents on these niches.
In mice, G-CSF causes a rapid and transient loss in morphologically recognizable mature osteoblasts, with marked reduction of the osteoid deposited by active osteoblasts at the endosteum, due in part to increased apoptosis. 110 Dynamic histomorphometry studies on endosteal bone surfaces in the secondary spongiosa of tibial metaphysis showed that bone formation was reduced by 90% during a 6-day treatment with G-CSF, whereas periosteal bone formation was not affected. 111 As a result, mRNA encoding cytokines essential to HSC maintenance in osteoblastic niches such as KL and ang-1 were significantly reduced at the endosteum. 111 In particular, CXCL12 expression, which is critical to HSPC retention within the BM, was reduced both at the endosteum and in the central BM, 83, 84, 111 suggesting that G-CSF not only downregulates endosteal niche function, but also CXCL12 expression by other cells such as CaR cells, osteoprogenitors and endothelial cells. A functional consequence of the decrease in CXCL12-, KL-and ang-1-mediated signaling could be the weakening of adhesive interactions between HSC and niche cells, and initiation of a motion away from the niche by HSC autonomous mechanisms requiring Gi proteins and small GTPases, such as Rac1, Rac2 and cdc42. This is supported by the fact that (1) loss of osteoblasts on endosteal surfaces starts as early as 24 h of G-CSF administration and precedes HSC mobilization, which only starts 48 h after the initiation of G-CSF treatment, 111 and
move from very poorly perfused niches in the BM to more perfused and perivascular areas of the BM. 65 An interesting parallel can be drawn between the observations that upon G-CSF treatment, (1) phenotypic HSC migrate from poorly perfused niches to more perfused niches, 65 and (2) phenotypic HSC proliferate more rapidly in the BM of G-CSF-treated animals 64 (IGW and JPL, unpublished data). This opens the question as to whether the exit of HSC from their endosteal niche causes entry into cell cycle before their egress into the circulation.
The sympathetic nervous system
The precise mechanisms by which endosteal niches are inhibited in response to mobilizing cytokines or chemotherapy are still poorly understood and clearly do not involve neutrophil serine proteases as mice deficient for dipeptidylprotease I (also called cathepsin C), which cannot mature active neutrophil elastase or cathepsin G, have similar osteoblast inhibition in response to G-CSF as WT mice. 111 A first type of mechanism was proposed by Paul Frenette's group and involves adrenergic sympathetic nerves. 30, 84, 112 Neonate mice knocked out for the uridine diphosphate-galactose ceramide galactosyltransferase (an enzyme necessary for myelin synthesis) or for dopamine b-hydroxylase (enzyme converting dopamine to norepinephrine) genes have abnormal osteoblast morphology at the endosteum with poor HSPC mobilization in response to G-CSF. Conversely, serial injections of 6-hydroxydopamine, which kill dopaminergic and adrenergic neurons, reduced osteoblast inhibition and HSPC mobilization in response to G-CSF. 84 A 3-week treatment with the b-adrenergic antagonist proranolol in WT adult mice reduced HSPC mobilization in response to G-CSF by 30%, whereas the b-adrenergic agonist clenbuterol partly rescued mobilization in dopamine b-hydroxylase knockout neonates and enhanced mobilization in control heterozygous littermates. 84 This suggests that noradrenergic nerves radiating through the BM and bone play an important role in mediating the response of osteoblasts, niches and HSC to G-CSF. In a separate work, these authors found that mouse HSPC are spontaneously released in the BM with a circadian periodicity, with oscillations in CXCL12 mRNA and protein in the BM following an opposite circadian pattern. Furthermore, denervation of the tibia by sectioning the sciatic and femoral nerves, or killing of adrenergic and dopaminergic nerves by injection of 6-hydroxydopamine abrogated oscillations in CXCL12 concentration and HSPC release into the blood. This effect was found to be mediated by b3-adrenergic receptors as a specific antagonist could prevent these oscillations, whereas a specific agonist could alone reduce CXCL12 concentration in the BM and elicit HSPC mobilization. 7 An interesting twist to these findings is that if blood from G-CSF-treated mice or humans is harvested in synchrony with the circadian time when HSPC spontaneously mobilize in steady-state, circulating HSPC harvest is significantly increased. 112 Although it is clear that b2-and b3-adrenergic receptors are important for HSPC mobilization in response to G-CSF, they are clearly not the only players. Indeed, in mice knocked out for both b2-and b3-adrenergic receptors, HSPC mobilization in response to G-CSF is reduced by 50% only. 113 Furthermore, although adrenergic nerves radiate through the bone, only endosteal osteoblasts are inhibited by G-CSF, and periosteal osteoblasts function normally. This observation clearly indicates that other cells from the BM compartment are also necessary for osteoblast inhibition in response to G-CSF. This was proven using reciprocal transplantation chimeras between G-CSF receptor (GCSFR) knockout and WT mice. Indeed, WT recipients reconstituted with GCSFR À/À BM (all hematopoietic cells are GCSFR À/À , while non-hematopoietic cells express GCSFR) have no osteoblast inhibition in response to G-CSF, whereas GCSFR À/À recipients reconstituted with WT BM had reduced osteoblast function in response to G-CSF. 110 Thus, BM leukocytes expressing GCSFR are required to inhibit osteoblasts.
Back to BM myeloid cells
Several experiments indicate that myeloid cells and particularly BM phagocytes play an important role in the G-CSF response and maintaining osteoblastic niche integrity. In the mouse, a population of F4/80 þ macrophages called osteomacs, which form a canopy over active osteoblasts, were found to be necessary for osteoblast differentiation in vitro and in vivo. 114 We have found that this layer of osteomacs vanishes from the endosteum, but not from the periosteum in response to G-CSF, suggesting that the loss of osteomacs may play a part in the inhibition of endosteal niches in response to G-CSF. 111 Furthermore, depletion of BM phagocytes with liposomes loaded with clodronate, a non-cell-permeable drug that has no cell toxicity in aqueous solution and requires active phagocytosis via liposomes to penetrate and kill cells, ablated osteomacs and osteoblasts, elicited mobilization of HSPC and LT-CRC within 48 h of administration, with marked downregulation of CXCL12, KL and ang-1 expression at the endosteum. 111 Similarly, Dan Link's group has found that activation of G-CSF signaling in monocytes/macrophages alone is sufficient to inhibit osteoblast function and elicit a robust HSPC mobilization. This was shown by introducing a GCSFR transgene under the control of the CD68 promoter to express the transgene specifically in monocytes and macrophages. These transgenic mice were then backcrossed into GCSFR À/À mice. The resulting CD68GCSFR Tg þ GCSFR À/À mice express GCSFR exclusively in CD68 þ monocytes/macrophages and were consequently neutropenic with normal numbers of monocytes. Once injected with G-CSF, these CD68GCSFR Tg þ GCSFR À/À mice mobilized HSPC as much as WT with inhibition of osteoblasts. 115 Therefore, activation of monocytes and macrophages may be sufficient to elicit both HSPC mobilization and inhibition of endosteal niches. The mechanisms by which these BM monocytes and macrophages maintain HSC niches and osteoblasts are unknown and remain to be investigated. However, the facts that the hypoxic state of the BM cavity raises dramatically during HSC mobilization with G-CSF or cyclophosphamide, 91 and that expression of hypoxia-inducible factor-1a is absolutely required for macrophage activation in vivo 116 suggests that increased hypoxia and the hypoxia-sensing pathway may play an important part in this mechanism. Similarly, the complement cascade is activated during mobilization, 50, 51, 117, 118 and complement proteins activate macrophages. 119, 120 Very importantly, impairment of osteoblastic niche function is not restricted to G-CSF. It is also observed during mobilization elicited by KIT Ligand and Flt3 ligand with similar downregulation of CXCL12 expression. 121 Nor is this phenomenon limited to mobilizing cytokines. We have found that a single injection of cyclophosphamide causes a rapid increase in osteoblast number and osteoid formation during the myeloablative phase of the treatment when HSPC do not mobilize, but this is followed by a complete ablation of osteoblasts, an arrest in bone formation, and reduced CXCL12 mRNA expression at the endosteum from day 6 to day 10, when HSPC are abundantly mobilized into the blood (IGW, NA Sims, JPL, unpublished data). This rapid swing from up-to downregulation of endosteal osteoblasts and CXC12 expression may explain why cyclophosphamide mobilizes better than G-CSF in mice. However, it must be noted that some mobilizing agents do not perturb endosteal niches. This is typically the case of the CXCR4 inhibitor AMD3100. Continuous administration of AMD3100 via osmotic pump mobilizes HSPC, but does not reduce osteoid formation, osteoblast number or expression of CXCL12, KL or ang-1 at the endosteum (IGW, JPL, NA Sims, LJ Bendall, unpublished data).
Some reports suggest that osteoclasts could play an important part in destabilizing endosteal niches and mobilizing HSPC in response to G-CSF. 122 These conclusions were based on the observation that (i) excessive bleeding, (ii) bacterial lipopolysaccharide and (iii) the osteoclast-stimulating cytokine RANKL (receptor activator for nuclear factor-kB ligand) all increase (a) the number of tartrate-resistant alkaline phosphatase-positive osteoclasts at the endosteum, (b) mobilize HSPC in the circulation and (c) decrease CXCL12 concentration in the BM fluid. In addition, cathepsin K, a cysteine protease produced specifically by osteoclasts, degrades CXCL12 and may therefore cause the drop in CXCL12 concentration observed in mobilized BM. 122 From these data, the authors concluded that osteoclasts play a unique role in the mobilization of HSPC in response to bleeding, bacterial infections, RANKL as well as G-CSF. Although osteoclasts could induce HSPC mobilization via cathepsin K in response to RANKL, bleeding or lipopolysaccharide, it is doubtful that osteoclasts play a major role in the clinically relevant mobilization of HSPC in response to G-CSF or chemotherapy. In 1998, we indeed showed that (1) bone degradation (as measured by urine concentration of the collagen degradation product deoxypyridinoline) and (2) the number of osteoclasts lining the endosteum both increased in humans and BALB/c mice following G-CSF administration. Importantly, however, this increase occurs very late, between days 6 and 8 in humans and 10-15 in BALB/c mice following G-CSF administration, at a stage when mobilization is over and HSPC are not circulating in the blood anymore. 109 It has been independently confirmed in C57BL/6 mice that osteoclast numbers do not increase during G-CSF administration when HSPC mobilize, but later when G-CSF is ceased and HSPC mobilization stops. 110 Furthermore, we find that pre-treatment of BALB/c mice with pamidronate 109 or C57BL/6 mice with zoledronate, two potent therapeutic inhibitors of osteoclasts, does not reduce mobilization of colony-forming cells and LT-CRC in response to G-CSF. 111 Interestingly, however, it has recently been published that osteoclasts mediate the accumulation of colony-forming units fibroblast, which correspond to multipotent mesenchymal progenitor cells, in the BM in response to G-CSF by releasing these colony-forming units fibroblast from the compact bone. 123 Again this accumulation of colony-forming units fibroblast in the BM, which was prevented by co-administration of osteoprotegerin, was not detectable before day 7 of G-CSF administration, 123 probably because osteoclasts do not accumulate in the BM before this time point. Therefore, while osteoclasts may promote the accumulation of colony-forming units fibroblast in the BM at late stages of G-CSF administration, they are unlikely to play a major role in the mobilization of HSPC and inhibition of osteoblastic niches, which occur within the first 4 days of G-CSF administration.
Are humans the same as mice?
Most data in this review on the existence of endosteal osteoblastic niches and how mobilization alters their function have been derived from mouse models. For obvious ethical SPOTLIGHT reasons, many of these experiments cannot be repeated in humans. So are human HSC niches similar? Reassuringly, several lines of evidence do suggest that human BM niches are organized similar to the mouse.
For a start, hematopoietic development in human and mouse embryos follows a very similar sequence, with emergence of definitive HSC from hemogenic endothelium in the placenta and dorsal aorta, migration of these fetal HSC to liver and spleen until ossification of bones and BM formation cavity occurs, and then finally HSC migration to the nascent BM in the boneforming cavity. 124, 125 Pioneering experiments show that osteoblasts isolated from trabecular bone that could support LT-CIC in vitro were performed using human osteoblasts and CD34 þ cells. 55, 56, 126, 127 Similar to mice, the density of CD34 þ KIT þ HSPC diminishes with increased distance from the endosteum in human cancellous bones. 128 In addition, similar to mouse MSC, a rare population of CD45 À CD146 þ adventitial reticular cells from the human BM, when transplanted subcutaneously in a hydroxyapatite-fibrin gel in immunocompromised mice, can spontaneously form ectopic bone ossicles containing a BM microenvironment and mouse leukocytes. 129 This suggests that similar to mice, the endosteum and osteoblast lineage cells in humans support HSC in the BM. Additional experiments are now required to confirm the existence of endosteal 'osteoblastic' niches in humans or primates. For instance, immunocompromised mice with ectopic human ossicles formed from CD45 À CD146 þ adventitial reticular cells could be irradiated and then transplanted with human CD34 þ CD38 À HSC to show direct interaction between human HSC and human osteoblast lineage cells. PTH treatment could be included to extend the observation that enhanced human bone formation is coupled with enhanced human HSC content. In this mouse model with human bone and human HSC, effects of Wnt antagonists, Notch signaling activation on bone formation and HSC content could further show the functional relationship between human osteoblasts and HSC. Similarly, HSC content in trabecular bone versus central BM could be compared using non-human primates or cadaveric human bones to confirm whether transplantable HSC (in a non-obese diabetes/severe-combined immunodeficiency xenotransplant model, for instance) are more frequent in trabecular bone than central BM.
In respect to mobilization, both human and mouse species are known to elicit similar responses to G-CSF and cyclophosphamide, such as release of neutrophil proteases in the BM, cleavage of VCAM-1, CXCL12 and inactivation of CXCR4. 34, 41 In regards to the response of the endosteal microenvironment to mobilizing agents, we have found that similar to mice, mobilization with cytokines such as G-CSF and KL results in a arrest in bone formation in humans, as suggested by a significant reduction in blood osteocalcin, which was correlated with the concentration of mobilized CFU-GM into the blood. 109 However, additional experiments must be conducted in non-human primates in order to confirm whether endosteal niches are shutdown during mobilization, such as bone formation arrest and disappearance of osteoblasts by histomorphometry, and downregulation of cytokines supporting HSC at the endosteum. Clinical trials could be designed to determine whether PTH or bisphosphonate treatment enhances HSPC mobilization in humans as observed in mice. Pre-treatment with PTH or bisphosphonates could be advantageous to mobilize patients with perturbed bone turn-over, such as menopausal women, elderly or multiple myeloma patients. Finally, the central role of Figure 1 Schematic representation of some of the interactions between HSC and their endosteal and vascular niches. Quiescent HSC are lodged in endosteal niche at two-cell diameters from osteoblasts, which are covered by a layer of osteomacs. These dormant HSC are in equilibrium with active, more proliferative HSC, which may reside in perivascular and more oxygenating niches. Osteoclasts provide soluble calcium ions that bind to CaR expressed by HSC. Proteins expressed by osteoblasts, osteoprogenitors, HSC and endothelial cells are in boxes. Details of these interactions are explained in the text.
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BM macrophages and osteomacs in maintaining niches and initiating HSC mobilization could be easily assessed in primates using clodronate-loaded liposomes, which kill phagocytic macrophages regardless of the species.
Conclusion
It is now clear that the bone and hematopoietic tissue are functionally intertwined, and that this relationship extends well beyond bone chewing osteoclasts formed from myeloid precursors. Deregulation of osteoblasts and osteoprogenitors can profoundly perturb hematopoiesis, and reciprocally, deregulation or stress of the hematopoietic system can profoundly perturb bone metabolism. The complex relationship between the bone, osteoblastic and mesenchymal lineages, innate immunity and HSPC function, lodgment and mobilization are summarized in Figures 1 and 2 .
A deeper understanding of these intimate relationships is needed. This could start by further identifying the cellular components of endosteal and osteoblastic niches that are obviously not limited to osteoblast lineage cells, but may also include adrenergic neurons, specialized trophic macrophages, reticular cells, mesenchymal stem cell and others. Molecular profiling (mRNA, microRNA, DNA methylations, histone modifications) of these purified cell components, as well as of the endosteal region of the BM, will provide novel clues on which additional factors are critical to HSC lodgment and retention at the niche and which factors control the switch between dormancy, self-renewal and asymmetric division. It has recently emerged that deregulation of and mutations in the BM microenvironment (for example, Dicer-1 and Shwachman-Diamond-Bodian syndrome gene in osteoprogenitors, retinoblastoma protein or retinoid acid receptor g in BM stromal cells) can favor the development of hematopoietic malignancies 78, 130, 131 introducing the novel concept of 'malignant niches'. A number of myelodysplasia cannot be easily cured by HSC transplantation, probably because the BM niches are dysfunctional. Detailed studies of the molecular interactions between HSC and their niches will therefore provide additional clues and potential therapeutic targets to restore the functionality of these niches, to improve HSC engraftment particularly in situations where the number of HSC in the graft is a limitation (for example, cord blood transplants), or to further boost HSC mobilization yields particularly in poor mobilizers. Figure 2 Diagram of events occurring in the endosteal landscape and BM space during HSPC mobilization with G-CSF.
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